simplSEQ Announces Data Showing Value of New DNA and RNA Isolation Technology Across Liquid Biopsy Applications
Poster Presented at Association for Molecular Pathology Annual Meeting Highlights Potential to Improve Diagnostic Success…
News
simplSEQ Receives Notice of Allowance from US Patent Office for Core Technology Patent
The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for simplSEQ’s…
simplSEQ to Present Novel Multi-Omic Technology at Sequencing, Finishing and Analysis in the Future Meeting
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an…
simplSEQ Completes Seed Round
Murrieta Genomics, the launch pad for genomic sequencing startups, has announced that simplSEQ, an incubator company,…
SimplSeq Lands $500,000 Seed Investment
The management team at SimplSeq is pleased to announce that it has received a $500,000…
SimplSeq Files Second Patent Around Breakthrough Technology
SimplSeq, the company dedicated to simplifying the genomic sequencing workflow process, has announced that a…
SimplSeq Retains Mind & Mill Marketing Agency
SimplSeq, the company dedicated to simplifying the genomic sequencing workflow process, has retained digital marketing…
Dr. John Spinosa Added to Executive Team
John C. Spinosa, M.D., Ph.D., has joined the executive management team as our Chief Medical…
SimplSEQ Featured in GenomeWeb Article
On Friday, January 29th 2021, an article about SimplSEQ was published by GenomeWeb, an online…
SimplSEQ Files Fourth Patent Application
SimplSEQ has filed its fourth patent application to protect our new sample preparation technology that…
simplSEQ Files Third Patent Application Designed to Improve DNA and RNA Sample Preparation
Murrieta Genomics has announced that its wholly owned subsidiary, SimplSeq Inc., has filed a new…
simplSEQ Team Focused on COVID-19 Testing Solutions
simplSEQ, the company dedicated to simplifying the genomic sequencing workflow process, has turned its attention…